In our analysis, after correcting for HR expression, HER2-positive breast cancer still showed significantly different mutations compared with HER2-low and HER2-zero breast cancer, but only marginal differences were found between HER2-low and HER2-zero tumors. The gene discussed is ERBB2; the disease is breast carcinoma.